Breast Cancer Awareness
Sara M. Tolaney, MD, MPH
Tolaney reports consulting or advising for Aadi Bio, ARC Therapeutics, Artios Biopharmaceuticals, Arvinas, AstraZeneca, Bayer, BeyondSpring Pharmaceuticals, BioNTech, Blueprint Medicines, Bristol-Myers Squibb/Systimmune, Circle Pharma, Cullinan Pharmaceutical, CytomX, Daiichi Sankyo, eFFECTOR, Eisai, Eli Lilly, Genentech/Roche, Gilead, Hengrui Pharmaceutical USA, Incyte Corp, Jazz Pharmaceuticals, Johnson&Johnson/AMBRX, Launch Therapeutics, Menarini/Stemline, Merck, Natera, Novartis, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Sumitovant, Tango Therapeutics, Umoja Biopharma, Zentalis, Zuellig Pharmaceuticals and Zymeworks; and receiving research funding from AstraZeneca, Bristol-Myers Squiqq/Systimmune, Cyclacel, Genentech/Roche, Gilead, Eisai, Eli Lilly, Exelixis, Menarini/Stemline, Merck, Nanostring, Novartis, OncoPep, Pfizer, Sanofi and Seattle Genetics.
VIDEO: Low-dose tamoxifen reduces toxicity with ‘very robust efficacy’
Transcript
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
So one of the things that I think is an improvement in prevention for breast cancer is the ability to utilize low dose tamoxifen. You know, we've had tamoxifen available for years as a method of prevention in patients who have high risk for developing breast cancer. So for example, patients who may have ductal carcinoma in situ that could eventually... They could eventually develop an invasive breast cancer. People who have atypical hyperplasia. We've had tamoxifen, which has really been found to reduce the risk of developing an invasive cancer by almost half. But it does have side effects, and we've seen now more recent data that using a low dose of tamoxifen is associated with a lot less in the way of toxicity, but actually seems to have very robust efficacy. So I think that's really a movement in the right direction in terms of prevention, and hopefully will allow for more patients to utilize endocrine therapy as prevention compared to what's been previously done.
